SLXN (Silexion Therapeutics) Total Operating Expense: $14.13 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SLXN Silexion Therapeutics Corp SLXN
13 GF Score
Price $0.37
! 1 Warning Sign
View Full Analysis

What is Silexion Therapeutics Total Operating Expense?

Silexion Therapeutics SLXN +0.73% 13 Total Operating Expense is $14.13 Mil as of Jun. 2026. GuruFocus rates SLXN with a GF Score™ of 13/100. The stock has 1 warning sign investors should review.

Silexion Therapeutics's Total Operating Expense for the three months ended in Jun. 2026 was $3.68 Mil. Silexion Therapeutics's Total Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 was $14.13 Mil.

Silexion Therapeutics Total Operating Expense Related Terms

Silexion Therapeutics Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Silexion Therapeutics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Silexion Therapeutics Total Operating Expense Chart

Silexion Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Operating Expense
3.86 4.68 12.57 11.63

Silexion Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.28 3.29 4.41 2.75 3.68
SLXN
13GF Score
Silexion Therapeutics Corp SLXN
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Silexion Therapeutics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $14.13 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $14.13 Mil mean?
Silexion Therapeutics (SLXN) has a Total Operating Expense of $14.13 Mil as of Jun. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Silexion Therapeutics and its competitors.
Is Silexion Therapeutics' Total Operating Expense too high?
Silexion Therapeutics' current Total Operating Expense is $14.13 Mil. Overall, Silexion Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Silexion Therapeutics' Total Operating Expense compare to DCOY and VRAX?
Silexion Therapeutics' Total Operating Expense of $14.13 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Silexion Therapeutics and its competitors. Silexion Therapeutics's current Total Operating Expense is $14.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Silexion Therapeutics stock overvalued right now?
Silexion Therapeutics (SLXN) has a current Total Operating Expense of $14.13 Mil. The current Total Operating Expense is $14.13 Mil. Silexion Therapeutics' overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Silexion Therapeutics (SLXN), the current Total Operating Expense is $14.13 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Silexion Therapeutics Business Description

Address 12 Abba Hillel Road, Ramat-Gan, ISR, 5250606
Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS). Its proprietary technology is designed to prompt tumor cells to degrade the messenger RNA (mRNA) that bridges the oncogene and the cellular protein synthesis machinery, utilizing small interfering RNA (siRNA) constructs that are chemically modified to enhance stability and cellular uptake while maintaining biological activity that interferes with the mRNA function. Its product candidate, SIL204, is a second-generation siRNA engineered to suppress the production of mutated KRAS proteins.
13GF Score

Get the complete analysis for SLXN

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.37
Price